Table 5 Relative excess risks (RERs) of death by morphology, age, disease stage and hormone receptor status (cases from the 10 registries with hormone receptor information available in ⩾60% operated cases)

		No of cases	RER	95% CI
Morphology	Infiltrating ductal carcinoma	1659	1
	Lobular and mixed carcinoma	297	0.58	0.37–0.91
	Comedocarcinoma	66	0.34	0.12–0.98
	Special types	111	0.35	0.12–0.99
	Medullary carcinoma	34	1.19	0.49–2.85
	NOS carcinoma	130	1.08	0.68–1.71
	Other carcinoma	49	1.38	0.72–2.63
Age	23–39	144	0.96	0.60–1.53
	40–49	426	0.71	0.49–1.02
	50–59	486	1
	60–99	1290	0.86	0.64–1.14
Stage	T1N0M0	819	1
	T2-3N0M0	443	3.82	1.94–7.51
	T1-3N+M0	789	9.26	5.05–16.97
	T4 M0	115	17.78	9.07–34.83
	M1	72	56.39	29.42–108.09
	Stage not specified	108	6.04	2.42–15.11
Hormone receptors	ER− PGR−^a	393	1
	ER+PGR+^b	980	0.32	0.24–0.43
	Either ER+ or PGR+^c	353	0.41	0.28–0.62
	Other^d	620	0.49	0.35–0.67

^aER− PGR−=both negative results.
^bER+ PGR+=both positive results.
^cEither ER+ or PGR+=tests performed with one positive result; in most cases, it is not known whether the other test was performed.
^dOther=tests not performed or unknown result.

Quick links

Search